NewsView printer-friendly version
Coherus BioSciences Management to Participate in Two Investor Healthcare Conferences in September
- Management participation in a fireside chat is scheduled at Baird’s 2018 Global Healthcare Conference on
Wednesday, September 5th at 10:50 a.m. ETtaking place in New York, NY.
- Management participation in a fireside chat is scheduled at the 13th Annual
Wells Fargo Securities Healthcare Conferenceon Thursday, September 6th at 8:00 a.m. ETtaking place in Boston, MA.
The audio portion of the presentations will be available on the investors page of the
Coherus is a leading biosimilar company that develops and commercializes high-quality therapeutics for major regulated markets. Biosimilars are intended for use in place of existing, branded biologics to treat a range of chronic and often life-threatening diseases, with the potential to reduce costs and expand patient access. Composed of a team of proven industry veterans with world-class expertise in process science, analytical characterization, protein production, sales & marketing and clinical-regulatory development, Coherus is positioned as a leader in the global biosimilar marketplace. Coherus is advancing three late-stage clinical products towards commercialization, UDENYCA™ (pegfilgrastim-cbqv), CHS-1420 (adalimumab biosimilar) and CHS-0214 (etanercept biosimilar), as well as developing a robust pipeline of future products in ophthalmology (including CHS-3351, a ranibizumab biosimilar, and CHS-2020, an aflibercept biosimilar), as well as CHS-131, a small molecule for nonalcoholic steatohepatitis (NASH) and multiple sclerosis. For additional information, please visit www.coherus.com.
Jean-Frédéric Viret, Ph.D.
Chief Financial Officer
+1 (650) 649-3546